受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 一、"画饼"背后的重组乱象 2026年伊始，A股市场便敲响了合规警钟。向日葵（维权）公司因重组预案涉嫌误导性陈述，正式被证 监会立案调查。向日葵的这场风波源于其在2025年9月披露的一份宏大且诱人的重大资产重组预案，宣 布计划收购兮璞材料100%股权及贝得药业40%股权。 然而，这份看似前途大好的"转型蓝图"，很快就在监管的显微镜下露出了马脚。根据媒体曝光和深交所 的深入问询，兮璞材料宣称的生产基地竟然是"空壳"。调查显示，其所谓的漳州和兰州基地并无实际产 能，其核心产品并非自主制造，而是通过简单的"低买高卖"赚取差价。 这种将贸易冒充高端制造的行为，严重误导了市场对资产价值的判断。 此外，该重组案中还隐藏着盘根错节的利益输送风险。交易对象中不仅包含实控人配偶控制的企业，其 供应商的股东甚至还是标的公司董事长的至亲。这种"一家亲"式的关联交易未被充分披露，加之实控人 深陷商业纠纷可能影响资产过户，使得 ...

Core Viewpoint - The company announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd., has proposed to be selected for the national centralized procurement of clarithromycin tablets and simvastatin tablets, with the procurement period extending until December 31, 2028 [1] Group 1 - The total sales revenue for the two products in 2024 is projected to be 38.99 million yuan, which accounts for 11.81% of the company's total revenue [1] - If the purchase and sales agreement is signed, it will expand the sales scale of the company [1]

本次拟中选产品克拉霉素片和辛伐他汀片均为国家医保目录产品，2024年度，克拉霉素片销售额3,718 万元，占公司同期主营业务收入的11.29%；辛伐他汀片销售额171万元，占公司同期主营业务收入的 0.52%。 格隆汇2月11日丨向日葵（维权）(300111.SZ)公布，子公司浙江贝得药业有限公司（简称"贝得药业"） 于近日参与了国家组织第1-8批(不含胰岛素专项采购，下同)集采药品协议期满品种接续采购的申报，根 据国家组织集采药品协议期满品种接续采购办公室（简称"接续采购办公室"）于2026年2月10日发布的 《国家组织集采药品协议期满品种接续采购拟中选结果公示》显示，贝得药业部分产品拟中选本次集中 采购。 ...

Core Viewpoint - The company Sunflower (300111.SZ) announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd. (referred to as "Beid Pharmaceutical"), has participated in the national centralized procurement for drugs whose agreements are expiring, and some of its products are expected to be selected in this procurement process [1] Group 1 - Beid Pharmaceutical has submitted applications for the national organized centralized procurement for drugs whose agreements are expiring, excluding insulin [1] - The results of the procurement process, published by the procurement office on February 10, 2026, indicate that some of Beid Pharmaceutical's products are likely to be selected [1] - The products expected to be selected include Clarithromycin Tablets and Simvastatin Tablets, both of which are included in the national medical insurance catalog [1]

智通财经APP讯，向日葵(300111.SZ)发布公告，公司子公司浙江贝得药业有限公司(以下简称"贝得药 业")于近日参与了国家组织第1-8批(不含胰岛素专项采购，下同)集采药品协议期满品种接续采购的申 报，根据国家组织集采药品协议期满品种接续采购办公室(以下简称"接续采购办公室")于2026年2月10 日发布的《国家组织集采药品协议期满品种接续采购拟中选结果公示》显示，贝得药业部分产品拟中选 本次集中采购。本次拟中选产品克拉霉素片和辛伐他汀片均为国家医保目录产品。 ...

向日葵公告，子公司贝得药业参与国家组织第1-8批集采药品协议期满品种接续采购，部分产品拟中 选。拟中选产品包括克拉霉素片和辛伐他汀片，采购周期自中选结果实际执行日起至2028年12月31日。 克拉霉素片2024年度销售额3718万元，占公司同期主营业务收入的11.29%；辛伐他汀片销售额171万 元，占公司同期主营业务收入的0.52%。 ...

拟中选的公告 证券代码：300111 证券简称：向日葵 公告编号：2026—007 浙江向日葵大健康科技股份有限公司 关于子公司参加国家组织集采药品协议期满品种接续采购 汀片销售额 171 万元，占公司同期主营业务收入的 0.52%。 本次接续采购由全国各省（自治区、直辖市）和新疆生产建设兵团组成采购 联盟，委托江苏省、河南省和广东省牵头，对原国家组织集采 1-8 批协议期满的 品种，开展全国统一接续采购工作。采购周期内，医药机构将优先使用本次药品 接续采购中选药品，并确保完成约定采购量。约定采购量以医药机构填报各企业 采购品种需求量为基数，按照中选价格梯度确定带量比例。 若公司后续签订购销协议并实施，将有利于进一步扩大中选产品的销售范围、 市场规模，提高产品市场占有率。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）子公司浙江贝得 药业有限公司（以下简称"贝得药业"）于近日参与了国家组织第 1-8 批(不含 胰岛素专项采购，下同) 集采药品协议期满品种接续采购的申报，根据国家组织 集采药品协议期满品种接续 ...

Core Viewpoint - The company Sunflower (300111) is facing legal actions due to alleged violations of information disclosure laws, leading to investigations by the China Securities Regulatory Commission (CSRC) and potential claims from investors [1][2]. Group 1: Legal Proceedings - On February 10, 2026, the Shaoxing Intermediate People's Court accepted a lawsuit filed by attorney Xu Feng on behalf of investors against Sunflower [1]. - Xu Feng's legal team is actively pursuing additional claims and accepting more investor mandates for compensation [1]. - The CSRC issued a notice on January 14, 2026, indicating that Sunflower is under investigation for suspected violations related to misleading statements in its restructuring proposal [1]. Group 2: Investigation Details - The Zhejiang Securities Regulatory Bureau initiated an investigation into Sunflower's restructuring proposal, which was disclosed on September 22, 2025, due to market concerns regarding the actual production capacity and business model [1]. - The investigation revealed that the restructuring proposal contained misleading statements, prompting the CSRC to take legal action [1]. Group 3: Investor Compensation - Investors who purchased Sunflower stock between September 22, 2025, and December 26, 2025, and sold or held their shares after December 26, 2025, may be eligible to file for compensation under securities law [2]. - Xu Feng has a history of successfully representing investors in similar cases, having handled nearly 200 stock compensation cases and currently managing around 300 ongoing claims [2].

Core Viewpoint - The company Xiangrikui (stock code: 300111) is under investigation by the China Securities Regulatory Commission (CSRC) for alleged misleading statements in its restructuring proposal, which has raised market concerns regarding the actual production capacity and business model of the restructuring target [2][4]. Group 1: Legal Proceedings - On February 10, 2026, the Shaoxing Intermediate People's Court accepted a compensation case filed by investors against Xiangrikui, represented by attorney Xu Feng from Shanghai Jiucheng Law Firm [1][3]. - The law firm is actively pursuing additional cases and accepting more investor claims for compensation related to the alleged violations [1][3]. Group 2: Regulatory Actions - On January 14, 2026, the CSRC issued a notice indicating that the Zhejiang Securities Regulatory Bureau has initiated an investigation into Xiangrikui's restructuring proposal due to suspected misleading statements [2][4]. - The investigation was prompted by market doubts regarding the actual production capacity and business model of the restructuring target, leading to a formal inquiry by the regulatory authority [2][4]. Group 3: Investor Claims - Investors who purchased Xiangrikui shares between September 22, 2025, and December 26, 2025, and sold or continued to hold the shares after December 26, 2025, are eligible to file for compensation based on the violations identified [3][5].

Core Viewpoint - The regulatory scrutiny on listed companies in China's A-share market has intensified, with multiple companies facing investigations and penalties for violations related to information disclosure and financial misconduct [2][10]. Group 1: Recent Investigations and Penalties - Two A-share companies, Tian Sheng New Materials and Yahui Long, were recently announced to be under investigation for suspected information disclosure violations [2][6]. - ST Funi was fined 6.5 million yuan for financial fraud involving collusion with a third-party company, which led to inflated profits of approximately 35.8 million yuan in 2020 [3][4]. - Rongbai Technology was fined 9.5 million yuan for misleading statements regarding a major contract, with the investigation concluding within a month [5][6]. Group 2: Overview of Violations - A total of eight A-share companies and four individuals have been investigated since the beginning of 2026, with the majority facing issues related to information disclosure violations [6][7]. - Specific cases include Baoxin Technology and its actual controller being investigated for information disclosure violations, and the independent director of *ST Dongjing being investigated for insider trading [7][8]. Group 3: Regulatory Environment - The regulatory environment has become increasingly stringent, with a significant number of companies being penalized for financial misconduct in 2025, particularly in the area of information disclosure violations [10][12]. - The China Securities Regulatory Commission (CSRC) has emphasized the need for a comprehensive system to combat financial fraud, indicating a shift towards proactive governance rather than reactive measures [12][13].